BioCentury
ARTICLE | Clinical News

Lycera reports Phase I data for solid tumor candidate LYC-55716

April 20, 2018 5:57 PM UTC

Lycera Corp. (Ann Arbor, Mich.) reported data from 26 evaluable patients with relapsed or refractory solid tumors in the Phase I portion of the Phase I/IIa ARGON trial showing that oral LYC-55716 led to one confirmed partial response and 12 cases of stable disease. The confirmed partial response occurred in a patient with advanced metastatic non-small cell lung cancer (NSCLC) with high PD-L1 expression who did not respond to first-line treatment with anti-PD-1 mAb Keytruda pembrolizumab or second-line treatment with carboplatin and Alimta pemetrexed.

Additionally, a patient with advanced, refractory sarcomatoid breast cancer who failed two prior lines of doublet chemotherapy had tumor volume regression of 19%. LYC-55716 was well tolerated with no dose-limiting toxicities (DLTs) reported at doses of up to twice-daily 450 mg LYC-55716. Data were presented at the American Association for Cancer Research meeting in Chicago...